In the US, uterine sarcoma is rare; 5058 cases of uterine sarcomas were estimated to occur in 2018. Uterine sarcomas account for about 3 to 7% of all uterine cancers (1 General reference Uterine sarcomas are a group of disparate, highly malignant cancers developing from the uterine corpus. Common manifestations include abnormal uterine bleeding and pelvic pain or mass. For suspected... read more ).
Risk factors for uterine sarcomas are
Prior pelvic radiation
Uterine sarcomas include
Leiomyosarcoma (the most common subtype [63%])
Endometrial stromal sarcoma (21%)
Undifferentiated uterine sarcoma
Rare uterine mesenchymal sarcoma subtypes include
Perivascular epithelioid cell tumor (PEComas)
Carcinosarcomas used to be categorized as sarcomas but are now considered and treated as high-grade epithelial tumors (carcinomas Endometrial Cancer Endometrial cancer is usually endometrioid adenocarcinoma. Typically, it manifests as postmenopausal uterine bleeding. Diagnosis is by biopsy. Staging is surgical. Treatment requires hysterectomy... read more ).
High-grade uterine sarcomas tend metastasize hematogenously, most often to the lungs; lymph node metastases are uncommon.
Symptoms and Signs of Uterine Sarcomas
Most sarcomas manifest as abnormal uterine bleeding and, less commonly, as pelvic pain, a feeling of fullness in the abdomen, a mass in the vagina, frequent urination, or a palpable pelvic mass.
Diagnosis of Uterine Sarcomas
Histology, most often after surgical removal
Symptoms suggesting uterine sarcoma usually prompt transvaginal ultrasonography and endometrial biopsy or dilation and curettage (D & C). However, these tests have limited sensitivity for sarcoma. Endometrial stromal sarcoma and uterine leiomyosarcoma are often incidentally diagnosed histologically after hysterectomy or myomectomy.
If cancer is identified preoperatively, CT or MRI is typically done. If uterine sarcoma is diagnosed after surgical removal, imaging is recommended, and surgical re-exploration can be considered to complete staging.
Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) is not usually done when patients have uterine sarcoma because this genetic syndrome increases risk of endometrial carcinoma, not sarcoma.
Staging is done surgically (see tables FIGO Surgical Staging of Uterine Sarcoma: Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Surgical Staging of Uterine Sarcoma: Leiomyosarcoma and Endometrial Stromal Sarcoma and FIGO Surgical Staging of Uterine Sarcoma: Adenosarcoma FIGO Surgical Staging of Uterine Sarcoma: Adenosarcoma ).
Prognosis for Uterine Sarcomas
Prognosis for patients with uterine sarcomas is generally poorer than that with endometrial carcinoma of similar stage; survival is generally poor when the cancer has spread beyond the uterus.
In one study, 5-year survival rates were
Stage I: 51%
Stage II: 13%
Stage III: 10%
Stage IV: 3%
Most commonly, the cancer recurs locally, in the abdomen, or the lungs.
Treatment of Uterine Sarcomas
Total abdominal hysterectomy and bilateral salpingo-oophorectomy
Usually adjuvant pelvic radiation therapy
Chemotherapy for advanced or recurrent cancers
(See also National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology: Uterine Sarcomas.)
Treatment of uterine sarcomas is total abdominal hysterectomy and bilateral salpingo-oophorectomy.
Uterine sarcomas should be removed en bloc; morcellation is contraindicated. If a specimen is fragmented during surgery, imaging is recommended to check for metastases, and re-exploration can be considered. Treatment with chemotherapy is also recommended.
The ovaries may be preserved in certain patients with early-stage uterine leiomyosarcoma if they wish to retain hormonal function. Additional surgical resection should be based on intraoperative findings.
Lymphadenectomy in patients with leiomyosarcoma or endometrial stromal sarcoma is not indicated because there is evidence that the risk of lymph node metastases is minimal (< 2%).
For inoperable sarcomas, pelvic radiation therapy with or without brachytherapy and/or systemic therapy is recommended.
Adjuvant radiation therapy is typically used and appears to delay local recurrence but does not improve overall survival rate.
Chemotherapy drugs are typically used when tumors are advanced or recur; drugs vary by tumor type.
Preferred regimens are
Docetaxel/gemcitabine (preferred for leiomyosarcoma)
Other recommended regimens include
Overall, response to chemotherapy is poor.
Endocrine therapy is used for patients with endometrial stromal sarcoma or hormone receptor–positive uterine leiomyosarcoma. Progestins are frequently effective. Endocrine therapy includes
GnRH (gonadotropin-releasing hormone) agonists
Uterine sarcomas are uncommon.
Symptoms include abnormal vaginal bleeding, a mass in the vagina, pelvic pain, a feeling of fullness in the abdomen, and frequent urination.
Prognosis is generally worse than that with endometrial carcinoma of similar stage.
Treat most patients with total abdominal hysterectomy, bilateral salpingo-oophorectomy, and adjuvant radiation.
Treat patients who have endometrial stroma sarcoma and hormone receptor–positive leiomyosarcomas with endocrine therapy.
Treat inoperable sarcomas with radiation therapy and/or chemotherapy.
The following is an English-language resource that may be useful. Please note that THE MANUAL is not responsible for the content of this resource.
National Cancer Institute: Uterine Cancer: This web site provides links to information about genetics and treatment of uterine sarcomas (a type of uterine cancer), as well as links to statistics and supportive and palliative care.
Drugs Mentioned In This Article
|Drug Name||Select Trade|
|Adriamycin, Adriamycin PFS, Adriamycin RDF, Rubex|
|Docefrez , Taxotere|
|Amen, Depo-Provera, Depo-subQ Provera 104, Provera|
|Megace, Megace ES|